The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita, MD, National Cancer Center Hospital, Tokyo, Japan, discusses the final results of a Phase II study of atezolizumab in relapsed/refractory extranodal NK/T-cell lymphoma. He highlights promising response rates, particularly in patients with PD-L1-positive disease, and the durable remissions observed in complete responders, underscoring the potential of immune checkpoint inhibition in this rare lymphoma subtype. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
